Twist Bioscience (TWST) Projected to Post Earnings on Monday

Twist Bioscience (NASDAQ:TWST) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $92.00 million for the quarter. Twist Bioscience has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.75) EPS. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Stock Performance

TWST opened at $40.11 on Monday. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -11.87 and a beta of 2.34. The firm’s fifty day simple moving average is $39.67 and its two-hundred day simple moving average is $44.29. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 52-week low of $30.32 and a 52-week high of $60.90.

Analysts Set New Price Targets

Several research firms recently issued reports on TWST. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research report on Friday, March 28th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.80.

Insider Activity

In other news, insider Dennis Cho sold 806 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now directly owns 112,221 shares in the company, valued at approximately $5,538,106.35. This represents a 0.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,432 shares of company stock valued at $1,038,170 in the last 90 days. Company insiders own 3.01% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.